|Bid||8,723.00 x 0|
|Ask||8,726.00 x 0|
|Day's range||8,631.00 - 8,766.00|
|52-week range||6,499.80 - 9,523.00|
|Beta (5Y monthly)||0.19|
|PE ratio (TTM)||108.68|
|Earnings date||09 Feb 2022 - 14 Feb 2022|
|Forward dividend & yield||2.02 (2.39%)|
|Ex-dividend date||12 Aug 2021|
|1y target est||98.40|
Dr. Robert G. Lahita MD, PhD, Director of the Institute for Autoimmune and Rheumatic Disease at Saint Joseph Health and author of Immunity Strong, joins Yahoo Finance Live to discuss the latest information on COVID-19 booster vaccinations, transmissibility, and the pressures felt by hospitals in remote regions.
WILMINGTON, Del., January 18, 2022--Positive results from the HIMALAYA Phase III trial showed a single priming dose of tremelimumab added to IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment.
WILMINGTON, Del., January 18, 2022--Positive results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) versus chemotherapy alone as a 1st-line treatment for patients with advanced biliary tract cancer (BTC).